To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are about to leave Sanofi campus website.

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v7.0) - Date of Preparation: July 2025

Welcome to Sanofi Campus UK

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Step Ahead Sanofi website

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

Whether you are focused on population health management, service design or budget planning, you can find here tools to address health inequalities and improve patient outcomes. Get quick access to product information, useful resources from therapy support to treatment guidelines, formulary and service support across various therapy areas.
Our field representatives are here to offer you a personalised support: from improving access to healthcare services to capability building, Sanofi can help design and implement strategies to reduce inequalities in your region.
Together, let's work towards a healthier, more equitable future for all.

payor

Payors - Health System Collaboration Portal

This section has resources that you may require for your formulary submissions and business cases or policy reviews. As well as product information, therapy support resources and treatment guidelines. You can download these materials to better support your decision making.

This document provides factual and technical information about Dupixent to support you with relevant document for local formulary applications.

Dupixent® (dupilumab) Formulary Application Support Pack

The impact on resource utilisation when using Dupixent in accordance with the SmPC.

Dupixent® (dupilumab) Optimisation Model

Simulate your savings from switching to Trurapi.

Trurapi®▼ (insulin aspart 100 units/mL)

We have a range of cost models available. If you need a more detailed modelling of our basal and rapid acting insulins portfolio, please reach out to one of our representatives.

Looking for something else?

black

This document provides information on estimating patients who might be eligable for Dupixent® via the COPD indication.

COPD - Eligible Population Estimator

Explore the impact that biologics could have on COPD services in regard to costs, admissions and stays within hospital.

COPD - Burden Analysis Model

An infographic showing the burden of COPD on hospital admissions, bed days and length of stay in England. For data relating to your ICB, please Get in Touch via the link below.

Burden of COPD Infographic

Get in Touch with the Health System Solutions Team

Resources to inform, aid and give insight across therapy areas, to help implement strategies to reduce inequalities in healthcare.

Formulary & Service Support

PAYOR

OUT-OF-TAXONOMY

Explore different joint working projects covering a range of disease areas, that deliver benefits to the patients, healthcare organisations and life sciences companies involved. 
Whenever possible, we publish the conclusions of our collaborative working so that others can learn from our experiences.

Sanofi undertakes collaborative working projects for the benefit of patients and/or the NHS.&nbsp;
These projects are entirely non promotional and are not linked in any way to any of our products.

Improving the pathway and experience for patients accessing the specialist Hidradenitis Suppurativa service at Salford Royal NHS Foundation trust.

Salford Royal NHS Foundation Trust Collaborative Working Project with Sanofi

A Collaborative working agreement between Sanofi and the Newcastle upon Tyne Hospitals NHS Foundation Trust to review and improve the homecare prescription pathway within the Hospital Trust

Collaborative Working Project between Sanofi and Newcastle upon Tyne Hospital Trust

Improve the patient journey and experience within the Dermatology Biologics service at Salford Care Organisation within Northern Care Alliance NHS Foundation Trust (NCA NHS FT).

Collaborative Working Project between Northern Care Alliance NHS Foundation Trust and Sanofi

This collaborative working project aims to identify areas for improvement in services, pathways, and care standards that could inform optimal utilisation of available transformation funding

St. Helens Diabetes Project

This collaborative working project aims to understand the different lipid pathways within the region, identifying the existing pressure points within services and whether inequity exists in this clinical area that contributes to overall health inequalities.

Wessex AHSN Lipid Pathway Mapping Project

The aim of the project is to improve patient outcomes and experiences when undergoing treatment within the BMT service in the University Hospital of Wales.

Cardiff and Vale University Health Board GvHD Project

Collaboration with healthcare organisations and the NHS to deliver real value beyond our medicines.

Let’s be Collaborative​ and Transformative

As part of our commitments around sustainability, Sanofi include carbon reduction plans in our NHS tenders, at the same time as tackling climate change and accelerating the reduction of our own environmental impact across the business.

Sanofi launched the Repen programme in 2024. This pilot programme forms part of Sanofi’s commitment to environmental protection. The used pens are posted back for recycling, free of charge to be recycled into metal, glass and plastic furniture.&nbsp;
Read more on the Repen recycling initiative that saves thousands of tonnes of waste each year.

RePen Programme

The NHS is one of the world's first healthcare systems to explicitly put sustainability in its targets which we are supporting in numerous ways.

Payors - Health System Collaboration Portal

Latest Resources

Formulary & Service Support

Let’s be Collaborative and Transformative

Let’s Be Sustainable

Payors - Health System Collaboration Portal

Latest Resources

Formulary & Service Support

Let’s be Collaborative​ and Transformative

Let’s Be Sustainable

Let’s be Collaborative and Transformative